[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Hall8Jack Jack Hall Jack Hall posts on X about $srpt, $dyn, $rna, $arwr the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::2598246906/interactions)  - X Week XXXXX -XX% - X Month XXXXXX +5.20% - X Months XXXXXXX +42% - X Year XXXXXXX +46% ### Mentions: XX [#](/creator/twitter::2598246906/posts_active)  - X Week XX -XX% - X Month XX -XX% - X Months XXX +18% - X Year XXX +126% ### Followers: XXXXX [#](/creator/twitter::2598246906/followers)  - X Week XXXXX +0.86% - X Month XXXXX +2.60% - X Months XXXXX +9.80% - X Year XXXXX +8.80% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::2598246906/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) [cryptocurrencies](/list/cryptocurrencies) [finance](/list/finance) **Social topic influence** [$srpt](/topic/$srpt) #13, [$dyn](/topic/$dyn) #12, [$rna](/topic/$rna) #4, [$arwr](/topic/$arwr), [$nvs](/topic/$nvs), [$pepg](/topic/$pepg), [$12b](/topic/$12b), [events](/topic/events), [will be](/topic/will-be), [$wve](/topic/$wve) **Top accounts mentioned or mentioned by** [@rnaianalyst](/creator/undefined) [@ttramyloid](/creator/undefined) [@gantosj](/creator/undefined) [@semodough](/creator/undefined) [@sanctuarybio](/creator/undefined) [@sportsbios](/creator/undefined) [@yachmod](/creator/undefined) [@jonu235](/creator/undefined) [@bionerd51](/creator/undefined) [@mauriceontw](/creator/undefined) [@biotechanalysst](/creator/undefined) [@jamesmclaw70633](/creator/undefined) [@biohazard3737](/creator/undefined) [@buylowsellhighh](/creator/undefined) [@bikepeddle](/creator/undefined) [@jfais20](/creator/undefined) [@adamfeuerstein](/creator/undefined) [@pharmdca](/creator/undefined) [@edcollins23](/creator/undefined) [@obryanjf](/creator/undefined) **Top assets mentioned** [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Dyne Therapeutics, Inc. Common Stock (DYN)](/topic/$dyn) [Avidity Biosciences, Inc. Common Stock (RNA)](/topic/$rna) [Arrowhead Research Corporation (ARWR)](/topic/$arwr) [Novartis AG (NVS)](/topic/$nvs) [Wave Life Sciences Ltd. Ordinary Shares (WVE)](/topic/$wve) [Ionis Pharmaceuticals, Inc. Common Stock (IONS)](/topic/$ions) [Vertex Protocol (VRTX)](/topic/$vrtx) [Alnylam Pharmaceuticals, Inc. (ALNY)](/topic/$alny) [Bitcoin Incognito (XBI)](/topic/$xbi) ### Top Social Posts Top posts by engagements in the last XX hours "$dyn safety not as good as $srpt Etep. Srpt also had ppmo51 which was discontinued due to safety and dyne-251 is very close analog. I would scrutinize ongoing chronic safety data very closely. This safety is very mixed and read note 5- ie why did they choose not to report on safety events after 8/19/25" [X Link](https://x.com/Hall8Jack/status/1998062623040868475) 2025-12-08T16:10Z 1641 followers, 1145 engagements "@bioinvestor24 Is this correct summary: $dyn dyne-251 produces 7fold increase of D over baseline $rna del-zota produces 4-5fold increase over baseline And according to this $srpt Etep produces 7fold increase over baseline" [X Link](https://x.com/Hall8Jack/status/1998184443383803973) 2025-12-09T00:14Z 1641 followers, XXX engagements "$arwr Related to $srpt subQ CNS Ataxias/Huntingtons Disease programs:" [X Link](https://x.com/Hall8Jack/status/1998769645952839969) 2025-12-10T14:59Z 1641 followers, XXX engagements "@BikeRieder Do you know if this will be owned by $arwr or this is one of the $srpt agreed to programs" [X Link](https://x.com/Hall8Jack/status/1998787712556605638) 2025-12-10T16:11Z 1641 followers, XXX engagements "@RNAiAnalyst @JamesMclaw70633 Be careful judging from their DMD programs $pepg may have a platform delivery tox issue/disadvantage (kidney/hypoMg) vs $rna . Which is particularly concerning as avidity had a clinical hold in DM1" [X Link](https://x.com/Hall8Jack/status/1989801640283836533) 2025-11-15T21:04Z 1638 followers, XXX engagements "@ArtsStocks If true how did $rna (BO for $12B by $nvs ) $dyn $pepg $vrtx expand into DM1 and/or FSHD w siRNAs and how did $wve expand into INHBE/obesity using siRNAs They have obtained no IP from $ions $alny . All of these companies ( $arwr ) have their own IP based on conjugated delivery" [X Link](https://x.com/Hall8Jack/status/1992999076674375722) 2025-11-24T16:49Z 1638 followers, XXX engagements "@ArtsStocks So are you saying $nvs wasted their time and $ with $rna BO" [X Link](https://x.com/Hall8Jack/status/1993002899291750783) 2025-11-24T17:04Z 1638 followers, XXX engagements "@BioTecIsFuture There are no effective drugs for DM1. Why do you think $nvs BO $rna for $12B Best in class will likely peak north of $2B per year- note these #s based on XX% market share:" [X Link](https://x.com/Hall8Jack/status/1993014422777053479) 2025-11-24T17:50Z 1638 followers, XXX engagements "@TimCarmichael3 This is a very good point- at this stage of trials $rna (DM1) $dyn (DMD) and $pepg (DMD) all had clinical holds with similar drugs. Not $arwr $srpt in DM1 and FSHD SO FAR" [X Link](https://x.com/Hall8Jack/status/1993360193208418629) 2025-11-25T16:44Z 1638 followers, XXX engagements "@BiotechAnalysst @SangamoTx So X other interested parties in $rna beside $nvs . Any chance any of them moved onto $arwr or $dyn $srpt etc" [X Link](https://x.com/Hall8Jack/status/1993719721389396401) 2025-11-26T16:33Z 1638 followers, XXX engagements "@avidresearch @JacobPlieth $srpt v $capr - apples to oranges but :" [X Link](https://x.com/Hall8Jack/status/1996275806637805578) 2025-12-03T17:50Z 1638 followers, XXX engagements "$srpt / Endeavor cohort 8/sirolimus related (also $rgnx $sldb etc #GeneTherapy ) :" [X Link](https://x.com/Hall8Jack/status/1996690038071988399) 2025-12-04T21:16Z 1640 followers, XXX engagements "@BikeRieder Little bit surprised $nvs went with $arwr deal for aro-snca/PD instead of aro-mapt/AD. Do you think aro-mapt too expensive asset or nvs saw higher prob of success for aro-snca $Srpt also passed on aro-mapt (in favor of Ataxia1-3; HD CNS assets) so same type of question" [X Link](https://x.com/Hall8Jack/status/1997665895124983933) 2025-12-07T13:53Z 1640 followers, XXX engagements "@LSinnv @BikeRieder CNS SC Programs: aro-mapt/AD (arwr) aro-atxn1/Ataxia1 aro-atxn3/Ataxia3 aro-htt/HD (srpt) aro-snca/PD (nvs)" [X Link](https://x.com/Hall8Jack/status/1997745088219496649) 2025-12-07T19:08Z 1640 followers, XXX engagements "@richtrades100 @biopharmacaster $dyn safety for x51 looks worse than $srpt . Will be key consideration" [X Link](https://x.com/Hall8Jack/status/1997997837771022847) 2025-12-08T11:53Z 1640 followers, XXX engagements "@richtrades100 @biopharmacaster Ppmo-51 had Mg problems. Not Eteplirsen. I stand by my statement. dyn51 had clinical hold. Not good for chronic tx. $dyn $srpt" [X Link](https://x.com/Hall8Jack/status/1997999290875048084) 2025-12-08T11:58Z 1640 followers, XXX engagements "@BiotechAnalysst Really need a detailed safety breakdown also" [X Link](https://x.com/Hall8Jack/status/1998103510416519569) 2025-12-08T18:52Z 1641 followers, XXX engagements "@BiotechAnalysst No new persistent thrombocytopenia for more than X months tough for a chronic tx. $dyn $rna $srpt" [X Link](https://x.com/Hall8Jack/status/1998118972646936878) 2025-12-08T19:54Z 1641 followers, XXX engagements "@FirstSquawk lol Nvda knew full well what was going on" [X Link](https://x.com/Hall8Jack/status/1998819451697758245) 2025-12-10T18:17Z 1641 followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Hall8Jack Jack Hall
Jack Hall posts on X about $srpt, $dyn, $rna, $arwr the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXX -XX%
- X Month XXXXXX +5.20%
- X Months XXXXXXX +42%
- X Year XXXXXXX +46%
Mentions: XX #
- X Week XX -XX%
- X Month XX -XX%
- X Months XXX +18%
- X Year XXX +126%
Followers: XXXXX #
- X Week XXXXX +0.86%
- X Month XXXXX +2.60%
- X Months XXXXX +9.80%
- X Year XXXXX +8.80%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence stocks cryptocurrencies finance
Social topic influence $srpt #13, $dyn #12, $rna #4, $arwr, $nvs, $pepg, $12b, events, will be, $wve
Top accounts mentioned or mentioned by @rnaianalyst @ttramyloid @gantosj @semodough @sanctuarybio @sportsbios @yachmod @jonu235 @bionerd51 @mauriceontw @biotechanalysst @jamesmclaw70633 @biohazard3737 @buylowsellhighh @bikepeddle @jfais20 @adamfeuerstein @pharmdca @edcollins23 @obryanjf
Top assets mentioned Sarepta Therapeutics, Inc. (SRPT) Dyne Therapeutics, Inc. Common Stock (DYN) Avidity Biosciences, Inc. Common Stock (RNA) Arrowhead Research Corporation (ARWR) Novartis AG (NVS) Wave Life Sciences Ltd. Ordinary Shares (WVE) Ionis Pharmaceuticals, Inc. Common Stock (IONS) Vertex Protocol (VRTX) Alnylam Pharmaceuticals, Inc. (ALNY) Bitcoin Incognito (XBI)
Top Social Posts
Top posts by engagements in the last XX hours
"$dyn safety not as good as $srpt Etep. Srpt also had ppmo51 which was discontinued due to safety and dyne-251 is very close analog. I would scrutinize ongoing chronic safety data very closely. This safety is very mixed and read note 5- ie why did they choose not to report on safety events after 8/19/25"
X Link 2025-12-08T16:10Z 1641 followers, 1145 engagements
"@bioinvestor24 Is this correct summary: $dyn dyne-251 produces 7fold increase of D over baseline $rna del-zota produces 4-5fold increase over baseline And according to this $srpt Etep produces 7fold increase over baseline"
X Link 2025-12-09T00:14Z 1641 followers, XXX engagements
"$arwr Related to $srpt subQ CNS Ataxias/Huntingtons Disease programs:"
X Link 2025-12-10T14:59Z 1641 followers, XXX engagements
"@BikeRieder Do you know if this will be owned by $arwr or this is one of the $srpt agreed to programs"
X Link 2025-12-10T16:11Z 1641 followers, XXX engagements
"@RNAiAnalyst @JamesMclaw70633 Be careful judging from their DMD programs $pepg may have a platform delivery tox issue/disadvantage (kidney/hypoMg) vs $rna . Which is particularly concerning as avidity had a clinical hold in DM1"
X Link 2025-11-15T21:04Z 1638 followers, XXX engagements
"@ArtsStocks If true how did $rna (BO for $12B by $nvs ) $dyn $pepg $vrtx expand into DM1 and/or FSHD w siRNAs and how did $wve expand into INHBE/obesity using siRNAs They have obtained no IP from $ions $alny . All of these companies ( $arwr ) have their own IP based on conjugated delivery"
X Link 2025-11-24T16:49Z 1638 followers, XXX engagements
"@ArtsStocks So are you saying $nvs wasted their time and $ with $rna BO"
X Link 2025-11-24T17:04Z 1638 followers, XXX engagements
"@BioTecIsFuture There are no effective drugs for DM1. Why do you think $nvs BO $rna for $12B Best in class will likely peak north of $2B per year- note these #s based on XX% market share:"
X Link 2025-11-24T17:50Z 1638 followers, XXX engagements
"@TimCarmichael3 This is a very good point- at this stage of trials $rna (DM1) $dyn (DMD) and $pepg (DMD) all had clinical holds with similar drugs. Not $arwr $srpt in DM1 and FSHD SO FAR"
X Link 2025-11-25T16:44Z 1638 followers, XXX engagements
"@BiotechAnalysst @SangamoTx So X other interested parties in $rna beside $nvs . Any chance any of them moved onto $arwr or $dyn $srpt etc"
X Link 2025-11-26T16:33Z 1638 followers, XXX engagements
"@avidresearch @JacobPlieth $srpt v $capr - apples to oranges but :"
X Link 2025-12-03T17:50Z 1638 followers, XXX engagements
"$srpt / Endeavor cohort 8/sirolimus related (also $rgnx $sldb etc #GeneTherapy ) :"
X Link 2025-12-04T21:16Z 1640 followers, XXX engagements
"@BikeRieder Little bit surprised $nvs went with $arwr deal for aro-snca/PD instead of aro-mapt/AD. Do you think aro-mapt too expensive asset or nvs saw higher prob of success for aro-snca $Srpt also passed on aro-mapt (in favor of Ataxia1-3; HD CNS assets) so same type of question"
X Link 2025-12-07T13:53Z 1640 followers, XXX engagements
"@LSinnv @BikeRieder CNS SC Programs: aro-mapt/AD (arwr) aro-atxn1/Ataxia1 aro-atxn3/Ataxia3 aro-htt/HD (srpt) aro-snca/PD (nvs)"
X Link 2025-12-07T19:08Z 1640 followers, XXX engagements
"@richtrades100 @biopharmacaster $dyn safety for x51 looks worse than $srpt . Will be key consideration"
X Link 2025-12-08T11:53Z 1640 followers, XXX engagements
"@richtrades100 @biopharmacaster Ppmo-51 had Mg problems. Not Eteplirsen. I stand by my statement. dyn51 had clinical hold. Not good for chronic tx. $dyn $srpt"
X Link 2025-12-08T11:58Z 1640 followers, XXX engagements
"@BiotechAnalysst Really need a detailed safety breakdown also"
X Link 2025-12-08T18:52Z 1641 followers, XXX engagements
"@BiotechAnalysst No new persistent thrombocytopenia for more than X months tough for a chronic tx. $dyn $rna $srpt"
X Link 2025-12-08T19:54Z 1641 followers, XXX engagements
"@FirstSquawk lol Nvda knew full well what was going on"
X Link 2025-12-10T18:17Z 1641 followers, XX engagements